Alan R. Williamson
Corporate Officer/Principal chez The European Molecular Biology Laboratory
Profil
Alan R.
Williamson is currently a Member at The European Molecular Biology Laboratory.
Previously, he held positions such as Chairman at the University of Glasgow and the University of California, Los Angeles, Director at Solexa Ltd., Non-Executive Director at deVGen NV, Director at Oxxon Therapeutics, Inc., Director at Pulmagen Therapeutics LLP, Vice President-Basic Research & Research Strategy at Merck & Co., Inc., Consultant at Abingworth LLP, and Principal at The National Institute For Medical Research and Glaxo, Inc.
Postes actifs de Alan R. Williamson
| Sociétés | Poste | Début |
|---|---|---|
| The European Molecular Biology Laboratory | Corporate Officer/Principal | - |
Anciens postes connus de Alan R. Williamson
| Sociétés | Poste | Fin |
|---|---|---|
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Corporate Officer/Principal | - |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Directeur/Membre du Conseil | - |
Solexa Ltd.
 Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Directeur/Membre du Conseil | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Health Technology |
| Glaxo, Inc. | |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
Solexa Ltd.
Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Health Technology |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
